NUTRIBAND INC (NTRB) Stock Overview
NASDAQ:NTRB - US67092M2089 - Common Stock
NTRB Key Statistics, Chart & Performance
The current stock price of NTRB is 6.45 USD. In the past month the price decreased by -14.46%. In the past year, price increased by 58.09%.
NTRB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.57 | 696.62B | ||
| JNJ | JOHNSON & JOHNSON | 17.65 | 425.05B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.03 | 248.19B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 14.15 | 245.90B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.31 | 245.16B | ||
| MRK | MERCK & CO. INC. | 11.04 | 212.29B | ||
| PFE | PFIZER INC | 7.35 | 141.68B | ||
| SNY | SANOFI-ADR | 11.33 | 122.68B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.01 | 96.09B | ||
| GSK | GSK PLC-SPON ADR | 8.79 | 80.29B | ||
| ZTS | ZOETIS INC | 24.89 | 68.60B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 49.6 | 46.99B |
Related stock screener links
About NTRB
Company Profile
Nutriband, Inc. engages in the development of a portfolio of transdermal pharmaceutical products. The company is headquartered in Orlando, Florida. The company went IPO on 2017-06-20. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. The company is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Company Info
NUTRIBAND INC
121 S Orange Ave Ste 1500
Orlando FLORIDA US
CEO: Gareth Sheridan
Employees: 13
Phone: 14073776695
NUTRIBAND INC / NTRB FAQ
What is the stock price of NUTRIBAND INC today?
The current stock price of NTRB is 6.45 USD. The price increased by 0.7% in the last trading session.
What is the ticker symbol for NUTRIBAND INC stock?
The exchange symbol of NUTRIBAND INC is NTRB and it is listed on the Nasdaq exchange.
On which exchange is NTRB stock listed?
NTRB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NUTRIBAND INC stock?
7 analysts have analysed NTRB and the average price target is 15.3 USD. This implies a price increase of 137.21% is expected in the next year compared to the current price of 6.45. Check the NUTRIBAND INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NUTRIBAND INC worth?
NUTRIBAND INC (NTRB) has a market capitalization of 71.92M USD. This makes NTRB a Micro Cap stock.
How many employees does NUTRIBAND INC have?
NUTRIBAND INC (NTRB) currently has 13 employees.
What are the support and resistance levels for NUTRIBAND INC (NTRB) stock?
NUTRIBAND INC (NTRB) has a support level at 6.43 and a resistance level at 6.46. Check the full technical report for a detailed analysis of NTRB support and resistance levels.
Is NUTRIBAND INC (NTRB) expected to grow?
The Revenue of NUTRIBAND INC (NTRB) is expected to grow by 528.03% in the next year. Check the estimates tab for more information on the NTRB EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy NUTRIBAND INC (NTRB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NTRB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NTRB, evaluating the profitability, health, valuation and growth aspects
- NUTRIBAND INC (NTRB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NUTRIBAND INC (NTRB) Sales and EPS estimates to see what analysts future expectations are.
- NUTRIBAND INC (NTRB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NUTRIBAND INC (NTRB) Insider and Institutional Ownership to learn about the owners and their transactions.
- NUTRIBAND INC (NTRB) Stock Chart to make your own analysis
- NUTRIBAND INC (NTRB) Latest news and press-releases to stay up to date.
Does NUTRIBAND INC (NTRB) stock pay dividends?
NTRB does not pay a dividend.
When does NUTRIBAND INC (NTRB) report earnings?
NUTRIBAND INC (NTRB) will report earnings on 2025-09-01.
What is the Price/Earnings (PE) ratio of NUTRIBAND INC (NTRB)?
NUTRIBAND INC (NTRB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.9).
What is the Short Interest ratio of NUTRIBAND INC (NTRB) stock?
The outstanding short interest for NUTRIBAND INC (NTRB) is 2.47% of its float. Check the ownership tab for more information on the NTRB short interest.
NTRB Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to NTRB. When comparing the yearly performance of all stocks, NTRB is one of the better performing stocks in the market, outperforming 85.55% of all stocks.
NTRB Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to NTRB. NTRB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
NTRB Financial Highlights
Over the last trailing twelve months NTRB reported a non-GAAP Earnings per Share(EPS) of -0.9. The EPS decreased by -17.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -162.11% | ||
| ROE | -195.43% | ||
| Debt/Equity | 0.01 |
NTRB Forecast & Estimates
7 analysts have analysed NTRB and the average price target is 15.3 USD. This implies a price increase of 137.21% is expected in the next year compared to the current price of 6.45.
For the next year, analysts expect an EPS growth of 6.67% and a revenue growth 528.03% for NTRB